INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 281 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $631,956 | -9.2% | 12,132 | +10.3% | 0.04% | -5.4% |
| Q2 2023 | $696,330 | +14.1% | 10,997 | -2.4% | 0.04% | -2.6% |
| Q1 2023 | $610,162 | +40.6% | 11,268 | +37.4% | 0.04% | +35.7% |
| Q4 2022 | $434,103 | +20.9% | 8,203 | +6.4% | 0.03% | +7.7% |
| Q3 2022 | $359,000 | -18.6% | 7,711 | -0.2% | 0.03% | -7.1% |
| Q2 2022 | $441,000 | -4.3% | 7,724 | +2.5% | 0.03% | +47.4% |
| Q1 2022 | $461,000 | +25.3% | 7,534 | +7.0% | 0.02% | +58.3% |
| Q4 2021 | $368,000 | +46.0% | 7,040 | +4.2% | 0.01% | +50.0% |
| Q3 2021 | $252,000 | -15.4% | 6,757 | -7.7% | 0.01% | -20.0% |
| Q2 2021 | $298,000 | +31.3% | 7,321 | +9.6% | 0.01% | +11.1% |
| Q1 2021 | $227,000 | +64.5% | 6,679 | -44.7% | 0.01% | 0.0% |
| Q4 2018 | $138,000 | -57.3% | 12,084 | -18.8% | 0.01% | -25.0% |
| Q3 2018 | $323,000 | – | 14,879 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |